Clinical Trial Update: Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis [Phase 1, Phase 2]

View source ↗

Summary

An early-phase clinical trial at Guangzhou Medical University is evaluating intrathecal delivery of a PD-1/VEGF bispecific antibody in combination with pemetrex…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis

Drugs mentioned

• PD-1/VEGF bispecific antibody
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Guangzhou Medical University | Conditions: Leptomeningeal Metastasis, Intrathecal Drug Delivery | Phase 1, Phase 2 | Status: RECRUITING